A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 54,274 shares of HRMY stock, worth $1.85 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
54,274
Previous 44,945 20.76%
Holding current value
$1.85 Million
Previous $1.36 Million 60.0%
% of portfolio
0.11%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$30.0 - $39.95 $279,870 - $372,693
9,329 Added 20.76%
54,274 $2.17 Million
Q2 2024

Jul 19, 2024

BUY
$28.81 - $33.01 $882,680 - $1.01 Million
30,638 Added 214.15%
44,945 $1.36 Million
Q1 2024

Apr 17, 2024

SELL
$29.93 - $35.06 $73,567 - $86,177
-2,458 Reduced 14.66%
14,307 $480,000
Q4 2023

Jan 10, 2024

SELL
$19.2 - $33.78 $540,096 - $950,231
-28,130 Reduced 62.66%
16,765 $541,000
Q3 2023

Oct 27, 2023

SELL
$31.89 - $39.03 $150,903 - $184,689
-4,732 Reduced 9.54%
44,895 $1.47 Million
Q2 2023

Aug 09, 2023

BUY
$30.5 - $37.4 $15,738 - $19,298
516 Added 1.05%
49,627 $1.75 Million
Q1 2023

Apr 20, 2023

BUY
$30.8 - $53.92 $35,882 - $62,816
1,165 Added 2.43%
49,111 $1.6 Million
Q4 2022

Jan 12, 2023

BUY
$45.4 - $60.91 $548,886 - $736,401
12,090 Added 33.72%
47,946 $2.64 Million
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $65,697 - $86,612
1,562 Added 4.55%
35,856 $1.59 Million
Q2 2022

Jul 19, 2022

BUY
$33.54 - $52.15 $153,445 - $238,586
4,575 Added 15.39%
34,294 $1.67 Million
Q1 2022

Apr 26, 2022

BUY
$33.14 - $51.13 $402,684 - $621,280
12,151 Added 69.17%
29,719 $1.45 Million
Q4 2021

Feb 14, 2022

BUY
$34.09 - $43.91 $598,893 - $771,410
17,568 New
17,568 $749,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.